Menu

Scientific Advisory Board

Michael Gilman, PhD

Michael Gilman, PhD

  • Founder and Chief Executive Officer of Padlock Therapeutics & Venture Partner at Atlas Venture
  • Former Executive Vice President of Research, Biogen Idec
  • Growing companies from inception to licensed products and M&As; immuno-inflammatory diseases, cancer and neurology
Steve Hitchcock, PhD

Steve Hitchcock, PhD

  • Head of Research, Takeda
  • Former Senior VP, Drug Discovery, Envoy Therapeutics
  • Adjunct Professor, Dept. of Molecular Therapeutics, Scripps Research Institute
Karin Conde-Knape, PhD

Karin Conde-Knape, PhD

  • VP Cardiovascular and Metabolism Scientific Innovation, J&J Innovation
  • Small and Large molecule early drug discovery, biomarkers and development
  • Diabetes, Obesity, Kidney Disease, Atherosclerosis, Dyslipidemia, Ophthalmology, Thrombosis
Stephen Squinto, PhD

Stephen Squinto, PhD

  • Venture Partner at OrbiMed Advisors
  • Former Co-founder & Executive Vice President at Alexion Pharmaceuticals, Inc.
  • Vast experience of over 25 years in the biotechnology industry
Tetsuyuki Maruyama, PhD

Tetsuyuki Maruyama, PhD

  • Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers LLP
  • Former General Manager, Head of Pharmaceutical Research Division, Takeda
  • Molecular and Cellular Neuroscience, CNS Research, Discovery, R&D, Cognitive and Neurodegenerative Disorders
Aya Jakobovits, PhD

Aya Jakobovits, PhD

  • Venture Partner, OrbiMed Israel Partners
  • Former president and CEO, Kite Pharma
  • R&D, preclinical & clinical dev., BD, and IP
Nissim Darvish, MD, DSc

Nissim Darvish, MD, DSc

  • Senior Managing Director, OrbiMed Israel Partners
  • Cardiology and Electrophysiology of excitable tissues
  • Businesses vision and medical knowledge combined into commercial success
Dror Haratz, MD

Dror Haratz, MD

  • CEO and Director, Vascular Biogenics Ltd.
  • Director of the Lipid Center and Chairman of the IRB Committee at Sheba Medical Center
  • Lipidology, Vascular biology, Immunology
Michal Preminger, PhD, MBA

Michal Preminger, PhD, MBA

  • Executive Director, Harvard University Office of Technology Development, Cambridge, MA
  • Drug discovery, Protein therapeutics, Marketing and BD
  • BOD member in several innovative life science companies